Welcome to the Limus Era.
SELUTION SLR™ Drug-Eluting Balloon is here.

With FDA approval for the treatment of coronary in-stent restenosis (ISR), SELUTION SLR™ Drug-Eluting Balloon (DEB) brings sustained sirolimus delivery to interventional cardiology in the U.S.

Join us at TCT 2026 to discover The Drug. The Data. The Delivery.

Request Additional Information Register for Cordis Events TCT 2026 Website

Learn About SELUTION SLR DEB

Partake in our Symposium Delivering Limus Differently: Advancing Coronary Treatment with SELUTION SLR Drug-Eluting Balloon on Sunday at 2:15 pm.
 

Join us for a night of connection and celebration.

Unwind with colleagues and industry leaders at our exclusive reception during TCT—great conversations, great company, and a toast to what’s ahead.

Next-Generation DEB Decision Lab

An interactive, case-based experience focused on the key clinical and technical decision points in DEB therapy.

Learn More

Select your region to access clinical information tailored to your location and regulatory environment.

US Healthcare Professionals International Healthcare Professionals

The Latest News from Cordis

Oct 6, 2026

Cordis SELUTION SLR SUSTANE™ PTA Drug Eluting Balloon achieves highest reported Primary Patency

The Cordis SELUTION SLR SUSTANE PTA Drug Eluting Balloon achieves highest reported Primary Patency in US IDE Trial

Read more

Sep 28, 2026

Cordis Honored at Premier, Inc.’s Annual Supplier Innovation Celebration

Innovation Celebration recognizes Cordis for Groundbreaking Healthcare Technologies

Read more

Sep 21, 2026

SELUTION SLR PTCA Drug-Eluting Balloon FDA Approval

SELUTION SLR™ Drug-Eluting Balloon Approved by FDA for In-Stent Restenosis: First and Only Sirolimus Drug-Eluting Balloon in the US.

Read more